Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss

Contributed by: Business Wire

Logo

Tags

Fitness & Nutrition

Clinical Trials

Other Health

Lifestyle

Health

Cosmetics

Consumer

Pharmaceutical

Retail

Galderma SA

More Like This

Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline

Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause

Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community

AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education